Downgrade follows Wolfe Research’s coverage initiation, citing comparable growth and cheaper Thermo Fisher on P/E multiples. Wolfe Research downgraded Danaher Corporation (DHR) to Peer Perform from Outperform, removing its price target after initiating coverage. The firm n
Roivant Sciences reports $4.3 billion in cash reserves and higher R&D spending for fiscal Q4 ended March 31, 2026. Guggenheim increased its price target for Roivant Sciences Ltd. (NASDAQ:ROIV) to $36 from $30, maintaining a Buy rating after the company’s fiscal Q4 earnings
HCA Healthcare, Inc. (NYSE:HCA) is one of the best healthcare stocks to buy with highest upside potential. HCA Healthcare, Inc. (NYSE:HCA) and The College of Health Care Professions announced on May 27 an agreement for HCA Healthcare to acquire ownership of CHCP CHC
BioNTech SE (NASDAQ:BNTX) is one of the best healthcare stocks to buy with highest upside potential. BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb Company announced on May 30 interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 clinical trial evaluating the
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best healthcare stocks to buy with highest upside potential. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on May 28 that maftivimab has been recommended by the World Health Organization’s (WHO) Therapeu
Medtronic plc (NYSE:MDT) is one of the best healthcare stocks to buy with highest upside potential. On May 21, Goldman Sachs reinstated coverage of Medtronic plc (NYSE:MDT) with a Neutral rating and set a $84 price target on the stock, which offers 7.5% upside potential</p
The Bank of Canada will deliver its latest interest rate decision on Wednesday and almost surely hold rates steady at 2.25%, the same place where rates have been since a cut in October. The market also sees very little chance of a rate hike at the July 15 meeting so there
Analysts see LLY reaching $1,500 within a year after 19% weight-loss data and four consecutive EPS beats boosted shares to 52-week highs. Eli Lilly shares surged to a 52-week high after retatrutide delivered 19% weight-loss results in Phase 3 trials, outpacing AstraZeneca’
TMC secures regulatory approval to explore 122,000 square kilometers for polymetallic nodules containing critical minerals. The National Oceanic and Atmospheric Administration approved TMC The Metals Company’s expanded exploration license for deep-sea mining in the Pacific
Goldman Sachs identifies two newly public stocks down at least 18% from IPO prices as compelling buys amid rising issuance activity. Goldman Sachs analysts have highlighted two recently listed stocks trading at least 18% below their debut prices as attractive entry points.
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.